Found: 15
Select item for more details and to access through your institution.
Practical Management of Everolimus-Related Toxicities in Patients with Advanced Solid Tumors.
- Published in:
- Oncology Research & Treatment, 2013, v. 36, n. 5, p. 295, doi. 10.1159/000350625
- By:
- Publication type:
- Article
Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2020, v. 27, n. 5, p. 1348, doi. 10.1245/s10434-019-08049-5
- By:
- Publication type:
- Article
Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Gene fusions are frequent in ACTH-secreting neuroendocrine neoplasms of the pancreas, but not in their non-pancreatic counterparts.
- Published in:
- Virchows Archiv: European Journal of Pathology, 2023, v. 482, n. 3, p. 507, doi. 10.1007/s00428-022-03484-4
- By:
- Publication type:
- Article
Effect of Lanreotide Depot/Autogel on Urinary 5‐Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
- Published in:
- Oncologist, 2019, v. 24, n. 4, p. 463, doi. 10.1634/theoncologist.2018-0217
- By:
- Publication type:
- Article
Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT‐3 and RADIANT‐4 trials.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 15, p. 2674, doi. 10.1002/cncr.33540
- By:
- Publication type:
- Article
Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas.
- Published in:
- Clinical Endocrinology, 2005, v. 62, n. 4, p. 434, doi. 10.1111/j.1365-2265.2005.02238.x
- By:
- Publication type:
- Article
Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications.
- Published in:
- 2017
- By:
- Publication type:
- journal article
High rate of Ki‐67 increase in entero‐pancreatic NET relapses after surgery with curative intent.
- Published in:
- Journal of Neuroendocrinology, 2022, v. 34, n. 10, p. 1, doi. 10.1111/jne.13193
- By:
- Publication type:
- Article
Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms.
- Published in:
- Neuroendocrinology, 2019, v. 108, n. 1, p. 18, doi. 10.1159/000493319
- By:
- Publication type:
- Article
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary.
- Published in:
- Neuroendocrinology, 2018, v. 106, n. 3, p. 211, doi. 10.1159/000477585
- By:
- Publication type:
- Article
Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
- Published in:
- Neuroendocrinology, 2015, v. 102, n. 1/2, p. 18, doi. 10.1159/000381715
- By:
- Publication type:
- Article
Poorly-Differentiated Endocrine Carcinomas of Midgut and Hindgut Origin.
- Published in:
- Neuroendocrinology, 2008, v. 87, n. 1, p. 40, doi. 10.1159/000109976
- By:
- Publication type:
- Article
Poorly Differentiated Carcinomas of the Foregut (Gastric, Duodenal and Pancreatic).
- Published in:
- Neuroendocrinology, 2006, v. 84, n. 3, p. 212, doi. 10.1159/000098013
- By:
- Publication type:
- Article
Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.
- Published in:
- OncoTargets & Therapy, 2017, v. 10, p. 5013, doi. 10.2147/OTT.S142087
- By:
- Publication type:
- Article